bioihbjkbjnl/mcl2 huggingface dataset:
Mesotherapy in the Treatment of Chronic Migraine
Condition: Chronic Migraine, Headache
MeSH terms: Migraine Disorders; Headache
Study type: Interventional

Summary: 
      Mesotherapy is a type of injection frequently used in clinics. It is a treatment procedure
      that involves the injection of some drugs under the skin or into the skin. Mesotherapy is
      used in musculoskeletal system diseases, but it is reported that the effects of its use in
      migraine are uncertain.
    

Detailed description: 
      Migraine is one of the types of headaches. For the diagnosis of chronic migraine, the
      headache must last more than 15 days. Nerve blocks, oral medication and neuromodulation are
      recommended for migraine treatment.Mesotherapy is a type of injection frequently used in
      clinics. It is a treatment procedure that involves the injection of some drugs under the skin
      or into the skin. Mesotherapy is used in musculoskeletal system diseases, but it is reported
      that the effects of its use in migraine are uncertain. This study was planned to show the
      effectiveness of mesotherapy in patients with migraine.
    

Intervention name(s): Lidocain
Intervention type(s): Drug
Intervention description(s): All participants treated with procaine and lidocaine injection for treatment.
Other intervention name(s): Proxicam
Intervention MeSH terms: Lidocaine
Intervention model: Single Group Assignment
Intervention model description: Retrospective analysis of the group that received treatment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: Mesotherapy; Chronic Migraine; pain; muscle; headache
Dairy Foods Compared to Dietary Supplements and Bone Health
Condition: Osteoporosis; Bone Loss; Osteopenia
MeSH terms: Osteoporosis; Bone Diseases, Metabolic
Study type: Interventional

Summary: 
      Does the consumption of dairy foods reduce the rate of bone loss in older women more than
      calcium and vitamin D supplements.
    

Detailed description: 
      Research indicates that bone health is dependent on multiple nutrients, not just calcium and
      vitamin D, leading to the conclusion that calcium from sources that include other bone
      enhancing nutrients may be more effective in maintaining bone integrity than calcium and
      vitamin D supplements. Several studies have examined the effects of calcium intake from dairy
      foods on different indicators of bone health. Reducing the rate of bone loss in
      postmenopausal women can reduce the risk of osteoporosis related fractures. Therefore we
      propose to study the effectiveness of 4 servings of milk and yogurt per day for 42 days
      compared to calcium and vitamin D supplements for 42 days to reduce calcium loss from the
      skeleton in post menopausal women. Postmenopausal women, approximately 50-65 years of age,
      will be studied. Each volunteer will receive both interventions in a cross-over design, in
      random order, separated by a 42 day washout period.
    

Intervention name(s): Intervention I; Intervention II
Intervention type(s): Other; Dietary Supplement
Intervention description(s): Four servings of dairy foods (milk and yogurt) per day for 42 days.; 1200 mg of supplemental calcium and 400 IU of vitamin D3 for 42 days
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Primary purpose: Prevention
Plant Pigments for Human Health: Impact of Lycopene and Anthocyanins on Bioefficacy of Provitamin A Carotenoids From Carrots
Condition: Healthy
Study type: Interventional

Summary: 
      The proposed research will help characterize the impact that simultaneous consumption of
      anthocyanins and carotenoids has on the bioavailability of the provitamin A carotenoids
      a-carotene and b-carotene and the non-provitamin A carotenoid lycopene, and on their
      respective antidiabetic activity in humans. The central hypothesis is that provitamin A
      carotenoids will be bioavailable from purple-red multicolored carrots in humans, and the
      co-ingestion of carotenoids and anthocyanins from these carrots will have synergistic impacts
      on their respective antioxidant and antidiabetic effects. This hypothesis will be assessed
      through a 53 day randomized crossover time course study that consists of three arms in which
      healthy males and females ages 18-40 (n = 12) will consume carrot juice prepared from red,
      purple-red, or purple carrots. During each arm, participants will switch the type of juice
      they consume and by the end of the third arm, all participants will have ingested juice made
      from all three carrot varieties. Blood will be collected at multiple time points over 72
      hours following consumption.
    


Intervention name(s): Purple-Red Carrot Juice; Red Carrot Juice; Purple Carrot Juice
Intervention type(s): Other; Other; Other
Intervention description(s): Purple-Red carrot juice contains provitamin A carotenoids (beta-carotene, alpha-carotene), the non-provitamin A carotenoid, lycopene, as well as anthocyanins; Red carrot juice contains provitamin A carotenoids (beta-carotene, alpha-carotene), and the non-provitamin A carotenoid, lycopene, but does NOT contain anthocyanins..; Purple carrot juice does NOT contain provitamin A carotenoids (beta-carotene, alpha-carotene), nor the non-provitamin A carotenoid, lycopene, but contains anthocyanins.
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Prevention
A 3-fold Crossover Bioequivalence Study Between Glucobay Orally Disintegrating Tablet (ODT) and Glucobay Standard Tablet
Condition: Diabetes Mellitus, Type 2
MeSH terms: Diabetes Mellitus, Type 2
Study type: Interventional
Phase: Phase 1

Summary: 
      To establish the bioequivalence between Glucobay ODT (Orally Disintegrating Tablet) taken
      without or with water and the Glucobay standard tablet taken with water
    


Intervention name(s): Acarbose (Glucobay ODT, BAYG5421); Acarbose (Glucobay ODT, BAYG5421); Acarbose (Glucobay, BAYG5421)
Intervention type(s): Drug; Drug; Drug
Intervention description(s): Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken without water; Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken with water; Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet; Day 2: oral sucrose load plus Glucobay standard tablet taken with water
Intervention MeSH terms: Acarbose
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: None (Open Label)
Keywords: Bioequivalence, acarbose, ODT
Bioequivalence Study on Vitamin D in Healthy Adults
Condition: Measure Absorption of Vitamin D in Blood
Study type: Interventional

Summary: 
      The objective of this study is to evaluate and compare the bioequivalence between a single
      oral dose of vitamin D3 gummy vitamin versus vitamin D3 tablet in healthy adults.
    

Detailed description: 
      The investigators hypothesize that the gummy and tablet preparations of vitamin D3 supplement
      will be biologically equivalent, as defined by the absence of a statistically significant
      difference in bioavailability measured as blood levels of vitamin D3 after administration of
      the same dose of gummy and tablet supplementation.
    

Intervention name(s): Vitafusion Extra Strength Vitamin D
Intervention type(s): Dietary Supplement
Intervention description(s): Monitor Vitamin D blood levels
Other intervention name(s): Nature Made Vitamin D
Intervention MeSH terms: Vitamin D; Ergocalciferols; Cholecalciferol; Vitamins
Allocation: Randomized
Intervention model: Crossover Assignment
Intervention model description: Randomized, cross-over, comparator-controlled
Masking: Single (Investigator)
Primary purpose: Other
Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?
Condition: Dry Eye
MeSH terms: Dry Eye Syndromes; Keratoconjunctivitis Sicca
Study type: Interventional
Phase: Phase 2/Phase 3

Summary: 
      Can Lyrica (Pregabalin) help prevent severe Dry Eye post LASIK surgery?
    

Detailed description: 
      Dry eye symptoms can occur after LASIK surgery. They generally get better with time but in
      some patients, they can persist. The investigators believe that in some individuals, dry eye
      symptoms after LASIK persist because the nerves in the cornea become hypersensitive. The
      investigators wish to study if a medication, called pregabalin, can protect corneal nerves at
      the time of LASIK surgery and decrease the frequency and severity of dry eye symptoms 6
      months after surgery. This medication has been used in a similar way to reduce the frequency
      of uncomfortable sensations after other surgeries (knee, abdomen) but has never been studied
      in LASIK surgery.
    

Intervention name(s): Pregabalin; Placebo
Intervention type(s): Drug; Drug
Intervention MeSH terms: Pregabalin
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Prevention
Keywords: laser-assisted in situ keratomileusis; dry eye symptoms; LASIK; prevention
Study Evaluating Multiple Doses Of ATN-103 In Subjects With Active Rheumatoid Arthritis
Condition: Active Rheumatoid Arthritis
MeSH terms: Arthritis; Arthritis, Rheumatoid
Study type: Interventional
Phase: Phase 1/Phase 2

Summary: 
      The purpose of this study is to evaluate the safety and efficacy of ATN-103 when administered
      to subjects with active rheumatoid arthritis compared with placebo. All subjects must be on a
      stable dose and route of methotrexate.
    


Intervention name(s): ATN-103; ATN-103; ATN-103; ATN-103; ATN-103; Placebo; Methotrexate
Intervention type(s): Drug; Drug; Drug; Drug; Drug; Drug; Drug
Intervention description(s): 10 mg every 4 weeks until week 12; 10 mg every 8 weeks until week 12; 30 mg every 4 weeks until week 12; 80 mg every 4 weeks until week 12; 80 mg every 8 weeks until week 12; Placebo every 4 weeks
Intervention MeSH terms: Methotrexate
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Alcohol Use Disorders in Schizophrenia
Condition: Schizophrenia; Mood Disorders; Alcohol Abuse; Alcohol Dependence
MeSH terms: Alcoholism; Schizophrenia; Mood Disorders
Study type: Interventional

Summary: 
      The purpose of the study is to evaluate a new treatment to help patients who have problems
      because of their use of alcohol. The treatment is called Behavioral Treatment for Alcohol
      Abuse in Schizophrenia (BTAAS).We are interested in determining whether BTAAS is more
      effective in reducing use than a supportive control treatment.
    

Detailed description: 
      Alcohol abuse and dependence in people with schizophrenia is a serious public health problem
      that is associated with poor treatment compliance, increased rates of relapse, increased
      levels of violence, and poor overall health and life functioning. Treating alcohol use
      disorders in people with schizophrenia is especially problematic, as schizophrenia is marked
      by symptoms and neurocognitive and psychosocial deficits that make it difficult for patients
      to engage in the higher level cognitive processes or the sustained, self-directed behaviors
      generally required to reduce drinking. To date there are no interventions for alcohol use
      disorders with solid empirical support that have been designed for or adapted to meet the
      needs of this multiply-handicapped population. In this study we will develop and pilot test a
      multifaceted behavioral intervention for treating schizophrenia patients with alcohol use
      disorders that will incorporate strategies that have been found to be effective in reducing
      drinking, but tailor them to meet the needs of this population. The intervention will contain
      several components, including: (1) pre-treatment motivational interviewing to increase
      engagement and motivation; (2) short-term goal setting at each session; (3) social skills and
      alcohol refusal skills training; (4) education and coping skills training for managing
      depression, stress and other forms of negative affect; (5) relapse prevention training; (6)
      case management aimed at networking with social supports in the participant's environment and
      linking patients with activities and social networks in the community in order to create a
      reinforcing, non-drinking environment.
    

Intervention name(s): Supportive Treatment in Addiction Recovery (STAR)
Intervention type(s): Behavioral
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: treatment; dual diagnosis
Brown Seaweed as a Breast Cancer Preventive
Condition: Breast Cancer
MeSH terms: Breast Neoplasms
Study type: Interventional
Phase: Phase 1/Phase 2

Summary: 
      Japanese postmenopausal women in Japan have about one ninth the rate of American
      postmenopausal women. Rates of breast cancer double even after just ten years among Japanese
      women who migrate to the US. Diet is thought to be an important factor, and the investigators
      were interested in whether dietary seaweed, with and without soy supplements, could influence
      known biomarkers of breast cancer risk in American women.
    

Detailed description: 
      33 healthy postmenopausal women were randomized to 6 wk seaweed then 1 wk seaweed plus soy or
      6 wk placebo then 1 wk placebo plus soy. Blood and urine samples were collected at the end of
      each treatment period and analyzed for estrogen, homocysteine, antioxidants, insulin-like
      growth factors and thyroid hormones. Urine was analyzed for phytoestrogens and iodine.
    

Intervention name(s): Seaweed and Soy Protein; Placebo and Soy Protein
Intervention type(s): Dietary Supplement; Dietary Supplement
Intervention description(s): 5 g/d Seaweed for 6 wks, followed by 5 g/d Seaweed + Soy Protein for 1 wk; 5 g/d Placebo for 6 wks, followed by 5 g/d Placebo + Soy Protein for 1 wk
Other intervention name(s): Solae Soy Food Ingredient Powder (AB1.2 HG 20CA 29); Alaria esculenta; Solae Nutritious Food Ingredient Powder (AB1.2 HG 20CA 29); Maltrin M100 maltodextrin (Grain Processing)
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Prevention
Keywords: Homocysteine; Insulin-like growth factor; Insulin-like growth factor binding protein; Serum estrogen; Urinary phytoestrogens; Thyroid hormones
Influence of Light on Sleep, Awakening, Electroencephalogram (EEG) and Cognitive Performances
Condition: Human Sleep and Chronobiology
Study type: Interventional

Summary: 
      The purpose of this project is to study the influence of light on sleep, wakefulness, EEG
      activity and cognitive performances. The study aim also to evaluate techniques for
      registration and analysis of the EEG over periods of time.
    


Intervention name(s): Application of white polychromatic light for 2h30 at different times of day
Intervention type(s): Other
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Basic Science
A Comparative Study of Botulinum Neurotoxin Type A in Treatment of Moderate to Severe Glabellar Frown Lines
Condition: Glabellar Frown Lines
Study type: Interventional
Phase: Phase 1/Phase 2

Summary: 
      Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison
      with Botox for a total of 12 weeks after the administration in treatment of glabellar frown
      lines.
    


Intervention name(s): Botulinum toxin type A
Intervention type(s): Drug
Intervention description(s): Total of 20U/0.5mL is intramuscularly administered to five points of the glabellar region, 4U/0.1mL each
Intervention MeSH terms: Botulinum Toxins; Botulinum Toxins, Type A; abobotulinumtoxinA
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Dose-Escalation Safety and Pharmacokinetic Study of ATX-101
Condition: Healthy
Study type: Interventional
Phase: Phase 1

Summary: 
      The purpose of this research is to evaluate the safety and pharmacokinetic profile of single
      doses of ATX-101
    

Detailed description: 
      This is a single center, open-label, dose-escalation study in which subjects will receive 4
      different dosage concentrations (3 dosing paradigms) of ATX-101 in a single dosing session.
    

Intervention name(s): ATX-101
Intervention type(s): Drug
Intervention description(s): ATX-101 single dose
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Keywords: Healthy volunteers
Plasma TMAO and Choline Levels in Individuals With Metabolic Syndrome - Comparison Between Eggs and Choline Supplement.
Condition: Coronary Artery Disease; Diabetes; Metabolic Syndrome
MeSH terms: Coronary Artery Disease; Metabolic Syndrome; Syndrome
Study type: Interventional

Summary: 
      The objective of this study is to determine the effects of consuming either 3 eggs per day
      and compare it to daily choline supplement (choline bitartrate) for a dose of approximately
      400 mg/day on plasma concentrations of high density lipoprotein cholesterol (HDL-c),
      trimethylamine N oxide (TMAO) and plasma choline. The goal is to determine if choline given
      as phosphatidyl choline (from eggs) will have a more beneficial effect on plasma choline and
      microbiota.
    

Detailed description: 
      Epidemiological data suggests that egg intake does not increase the risk for cardiovascular
      disease (CVD). In fact eggs are a good source of phosphatidyl choline (PC) and choline has a
      number of metabolic roles including lipid metabolism, membrane structure, liver health and a
      neurotransmitter. Recent reports that choline may be metabolized by the intestinal microbiota
      into TMAO, a compound that may increase the risk for heart disease. It is not clear how much
      egg contribute to TMAO formation in individuals with metabolic syndrome.

      Therefore the objective of this study is to determine the impact of daily intake of 3 eggs
      versus a choline supplement on plasma TMAO and other biomarkers for CVD risk and also to
      assess if there are changes in microbiota with these interventions that might lead to the
      increases of TMAO in plasma.
    

Intervention name(s): Eggs
Intervention type(s): Other
Intervention description(s): Eggs: Consume 3 eggs per day for 4 weeks Choline supplement: Consume 1.5 pills per day for 4 weeks
Other intervention name(s): Dietary supplement (choline bitartrate)
Intervention MeSH terms: Choline
Allocation: Randomized
Intervention model: Crossover Assignment
Intervention model description: Randomized crossover design
Masking: None (Open Label)
Primary purpose: Prevention
Keywords: eggs,; choline; metabolic syndrome; TMAO
Effects of Traumeel®S Tablets on Exercise Induced Muscle Damage and Muscle Soreness
Condition: Exercise-induced Muscle Soreness
MeSH terms: Myalgia
Study type: Interventional
Phase: Phase 1

Summary: 
      To investigate and compare the effects of Traumeel®S tablets versus placebo on exercise
      induced muscle damage and muscle soreness for 72 hours after strenuous eccentric exercise
      test on downhill treadmill.
    


Intervention name(s): Traumeel; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning; oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Muscle; exercise; soreness; Damage; Traumeel
A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage
Condition: Non-alcoholic Steatohepatitis
MeSH terms: Fatty Liver; Non-alcoholic Fatty Liver Disease
Study type: Interventional
Phase: Phase 2

Summary: 
      Semaglutide is a medicine studied in patients with non-alcoholic steatohepatitis (NASH), as
      it may improve liver damage. Participants will either get semaglutide or placebo (a dummy
      medicine) - which treatment participants get is decided by chance. The study will last for
      about 61 weeks in total. Participants will have 10 clinic visits and 3 phone calls with the
      study doctor or staff during the study. Some of the clinic visits may be spread over more
      days. Participants will need to inject themselves with medicine under the skin. Participants
      will have to do this once a week for 48 weeks. The study includes magnetic resonance imaging
      (MRI) scans of the liver, 1 or 2 liver tissue samples, ultrasound scans of the stomach and a
      possible examination of the food pipe. For some tests participants may need to remove some
      items of clothing. Participants will stop in the study if the doctor thinks that there are
      any risks for their health. The information collected from participants during the study may
      help them and other patients with NASH in the future. Women cannot take part if pregnant,
      breast-feeding or planning to become pregnant during the study period.
    


Intervention name(s): Semaglutide; Placebo (semaglutide)
Intervention type(s): Drug; Drug
Intervention description(s): Semaglutide given subcutaneously (s.c., under the skin) once-weekly for 48 weeks; Semaglutide placebo s.c. given once-weekly for 48 weeks
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment